We outline a list of considerations for regulatory agencies, manufacturing companies, international and national professional societies, funding bodies, researchers, healthcare professionals, and people with diabetes to take into careful consideration (Diabetologia)
Diabetes News
Tag: insulin pump
Launch of the ABCD audit for the Omnipod insulin pump
ABCD is pleased to announce the launch of the ABCD International Omnipod audit and would like to invite you to take part (ABCD)
Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study
The small subset of participants using routine CGM and insulin pumps had fewer hypoglycemic and hyperglycemic excursions and lower HbA1c levels. Thus, strategies to lower meal-stimulated hyperglycemia during the day and prevent hypoglycemia at night are relevant clinical goals in older patients with type 1 diabetes (Diabetes Care)
Does Current Diabetes Technology Improve Metabolic Control? A Cross-Sectional Study on the Use of Insulin Pumps and Continuous Glucose Monitoring Devices in a Nationwide Pediatric Population
Despite the broad use of diabetes technology, as many as 61% of our pediatric cohort did not reach the HbA1c target recommended by the International Society for Pediatric and Adolescent Diabetes (Diabetes Therapy)
Temporal Trends and Contemporary Use of Insulin Pump Therapy and Glucose Monitoring Among Children, Adolescents, and Adults With Type 1 Diabetes Between 1995 and 2017
Since 1995, insulin pump use has continuously increased, and insulin pump therapy is now standard in patients aged <15 years. CGM use sharply rose in recent years, particularly in young children (Diabetes Care)
National Diabetes Audit – Insulin Pump Report 2017-18
This report provides information on people with Type 1 diabetes on an insulin pump at National, Local Health Board (LHB), and Specialist Diabetes Service level for the audit period 2017-18 (NHS Digital)
Use of sensor‐integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real‐world study in the UK
Real‐world UK data show that increasing automation of insulin suspension reduces hypoglycaemia exposure in people with Type 1 diabetes (Diabetic Medicine)
Insulin Bolus Administration in Insulin Pump Therapy: Effect of Bolus Delivery Speed on Insulin Absorption from Subcutaneous Tissue
Results suggest that insulin bolus delivery with fast delivery speed may result in more rapid insulin absorption and, thus, may provide a better control of meal-related glucose excursions than that obtained with bolus delivery using slow delivery speeds. Our findings may have important implications for the future design of the bolus delivery unit of insulin pumps (Diabetes Technology and Therapeutics)
Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: The pumpkin multicenter randomized controlled trial
CSII has substantial psychosocial benefits. PROs demonstrate these benefits (Pediatric Diabetes)
National Diabetes Audit – Insulin Pump Report 2016-17
Report for people with Type 1 diabetes on an insulin pump at National, LHB, and Hospital/Trust level for the Audit period 2016-17 (NHS Digital)
Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes
Among young patients with type 1 diabetes, insulin pump therapy, compared with insulin injection therapy, was associated with lower risks of severe hypoglycemia and diabetic ketoacidosis and with better glycemic control during the most recent year of therapy. (JAMA)
Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial
Relative to conventional and sensor-augmented insulin pump therapy, the bihormonal bionic pancreas, initialised only with participant weight, was able to achieve superior glycaemic regulation without the need for carbohydrate counting. Larger and longer studies are needed to establish the long-term benefits and risks of automated glycaemic management with a bihormonal bionic pancreas (Lancet)
Insulin pump-associated adverse events are common, but not associated with glycemic control, socio-economic status, or pump/infusion set type
Insulin pump-associated AEs are very common. However, few variables are predictive of them with no relationships seen with glycaemic control, socio-economic status, pump manufacturer or infusion set type. Based on these findings, AEs should be anticipated in both adults and children, with anticipatory patient education and training recommended for their successful and safe use (Acta Diabetologica)
Sustained Efficacy of Insulin Pump Therapy in Type 2 Diabetes: 9-Year Follow-up in a Cohort of 161 Patients
This retrospective analysis demonstrates the sustained efficacy of insulin pump therapy in patients with type 2 diabetes with MDI failure (Diabetes Care)
National Diabetes Insulin Pump Audit Report, 2013-15
The Insulin Pump Audit is part of the National Diabetes Audit programme (NDA), and is commissioned by the Healthcare Quality Improvement Partnership (HQIP) as part of the National Clinical Audit programme (NCA)
Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes
Evidence-based recommendations on the MiniMed Paradigm Veo and Vibe and G4 PLATINUM CGM sensor-augmented pump therapy systems, which combine continuous glucose monitoring and continuous subcutaneous insulin infusion, for people with type 1 diabetes (NICE)
Sustained efficacy of insulin pump therapy, compared with multiple daily injections, in type 2 diabetes: 12-month data from the OpT2mise randomized trial
Pump therapy has a sustained, durable, effect on glycaemic control in uncontrolled type 2 diabetes (Diabetes, Obesity and Metabolism)
Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes
The improved mean glycaemia and reduced hypoglycaemia with the bionic pancreas relative to insulin pump therapy in preadolescent children with type 1 diabetes in a diabetes camp setting is a promising finding (The Lancet Diabetes & Endocrinology)
Initiation of insulin pump therapy in children at diagnosis of type 1 diabetes resulted in improved long-term glycemic control
Initiation of IPT at diagnosis of type 1 diabetes in children resulted in consistently lower HbA1c with no apparent change in hypoglycemia, DKA, or QOL (Pediatric Diabetes)
Clinical inertia in intensifying therapy among people with type 2 diabetes treated with basal insulin
Strategies should be developed to increase the number of patients undergoing therapy intensification and to reduce the delay in intensifying therapy for suitable patients on basal insulin. Initiatives to support patients continuing on insulin are also required (Diabetes, Obesity and Metabolism)
Glycosmedia is also available as an App: